{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:46:28Z","timestamp":1793810788618,"version":"4.6.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The aim was to identify whether malignant diseases increase the risk of medication-related osteonecrosis of the jaw (MRONJ) occurrence when patients are exposed to bisphosphonate, antiresorptive or antiangiogenic drugs. To analyze related factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic literature searching was performed in PubMed, Embase, and Google Scholar for studies with information about whether patients have malignant diseases. Patients involved must be treated with MRONJ-related drugs and at high risk of developing MRONJ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 6 cohort studies and 3 case-control studies were included. Analysis according 9 studies shows that malignant diseases have significant influence on MRONJ occurrence (risk ratio (RR): 2.62; 95% confidence interval (95% CI): 1.58\u20134.33;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0002). Subgroup analysis according 6 cohort studies also shows that malignant diseases significantly affect MRONJ occurrence (RR: 3.50; 95% CI: 1.63\u20137.52;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001). Chemotherapy have no obvious influence on MRONJ occurrence (RR: 1.64; 95% CI: 0.79\u20133.39;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.18). Intravenous drug administration significantly influences MRONJ occurrence (RR: 2.67; 95% CI: 1.27\u20135.58;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.009).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Patients with malignant diseases have higher risk of MRONJ occurrence when exposed to bisphosphonate, antiresorptive, or antiangiogenic drugs. Cumulative dosages from intravenous drugs administration contribute to MRONJ developing. Prevention of MRONJ in patients with malignancy should be emphasized.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/scs.0000000000009033","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T05:42:56Z","timestamp":1664775776000},"page":"669-673","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Association Between Malignant Diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis"],"prefix":"10.1097","volume":"34","author":[{"given":"Sheng","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"R1-20260427","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R2-20260427","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","article-title":"Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015","volume":"27","author":"Khan","year":"2016","journal-title":"Osteoporos Int"},{"key":"R3-20260427","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"R4-20260427","first-page":"e253","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study","volume":"168","author":"Capocci","year":"2017","journal-title":"Clin Ter"},{"key":"R5-20260427","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5125\/jkaoms.2019.45.2.108","article-title":"Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation","volume":"45","author":"Sahin","year":"2019","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"R6-20260427","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.coms.2015.06.003","article-title":"The frequency of medication-related osteonecrosis of the jaw and its associated risk factors","volume":"27","author":"Dodson","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"R7-20260427","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"R8-20260427","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R9-20260427","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jcms.2019.03.007","article-title":"Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? a matched case-control study","volume":"47","author":"Bedogni","year":"2019","journal-title":"J Craniomaxillofac Surg"},{"key":"R10-20260427","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.joms.2009.10.026","article-title":"Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction","volume":"68","author":"Saia","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"R11-20260427","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"R12-20260427","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1038\/sj.bdj.2013.327","article-title":"A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King\u2019s College Hospital","volume":"214","author":"Taylor","year":"2013","journal-title":"Br Dent J"},{"key":"R13-20260427","first-page":"2265","article-title":"Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study","volume":"28","author":"Soares","year":"2020","journal-title":"Support Care Cancer"},{"key":"R14-20260427","doi-asserted-by":"crossref","first-page":"20160260","DOI":"10.1259\/dmfr.20160260","article-title":"Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy","volume":"46","author":"Koth","year":"2017","journal-title":"Dentomaxillofac Radiol"},{"key":"R15-20260427","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/odi.13046","article-title":"Systemic comorbidities are associated with medication-related osteonecrosis of the jaws: case-control study","volume":"25","author":"McGowan","year":"2019","journal-title":"Oral Dis"},{"key":"R16-20260427","first-page":"E114","article-title":"Meaning and limitation of cortical bone width measurement with DentaScan in medication-related osteonecrosis of the jaws","volume":"62","author":"Iwata","year":"2017","journal-title":"Kobe J Med Sci"},{"key":"R17-20260427","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study","volume":"41","author":"Yamazaki","year":"2012","journal-title":"Int J Oral Maxillofac Surg"},{"key":"R18-20260427","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-20260427","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","article-title":"Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"R20-20260427","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","article-title":"Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis","volume":"89","author":"Rizzoli","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"R21-20260427","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8040","article-title":"A systematic review of the role of bisphosphonates in metastatic disease","volume":"8","author":"Ross","year":"2004","journal-title":"Health Technol Assess"},{"key":"R22-20260427","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1210\/jc.2015-1794","article-title":"Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer","volume":"100","author":"Sim Ie","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-20260427","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"key":"R24-20260427","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0036-1592367","article-title":"Bisphosphonate and medication-related osteonecrosis of the jaw: a review","volume":"20","author":"Mucke","year":"2016","journal-title":"Semin Musculoskelet Radiol"},{"key":"R25-20260427","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","article-title":"Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study","volume":"30","author":"Hasegawa","year":"2019","journal-title":"Osteoporos Int"},{"key":"R26-20260427","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/odi.12708","article-title":"Risk factors for medication-related osteonecrosis of the jaws: a systematic review","volume":"24","author":"McGowan","year":"2018","journal-title":"Oral Dis"},{"key":"R27-20260427","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.oraloncology.2009.01.002","article-title":"Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update","volume":"45","author":"Bagan","year":"2009","journal-title":"Oral Oncol"},{"key":"R28-20260427","first-page":"181","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. a critical review","volume":"59","author":"Vescovi","year":"2010","journal-title":"Minerva Stomatol"},{"key":"R29-20260427","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijom.2011.02.002","article-title":"Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw","volume":"40","author":"Katz","year":"2011","journal-title":"Int J Oral Maxillofac Surg"},{"key":"R30-20260427","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"R31-20260427","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jbmr.23","article-title":"Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats","volume":"25","author":"Hokugo","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R32-20260427","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00784-014-1273-7","article-title":"Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases","volume":"19","author":"Hoefert","year":"2015","journal-title":"Clin Oral Investig"},{"key":"R33-20260427","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijom.2011.12.016","article-title":"Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease","volume":"41","author":"Marx","year":"2012","journal-title":"Int J Oral Maxillofac Surg"},{"key":"R34-20260427","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.3390\/jcm10204762","article-title":"Cancer patients at risk for medication-related osteonecrosis of the jaw. a case and control study analyzing predictors of MRONJ onset","volume":"10","author":"Marciano","year":"2021","journal-title":"J Clin Med"},{"key":"R35-20260427","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs. zoledronic acid: a systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"R36-20260427","first-page":"7047","article-title":"One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)","volume":"30","author":"Fusco","year":"2022","journal-title":"Support Care Cancer"}],"container-title":["Journal of Craniofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SCS.0000000000009033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:33Z","timestamp":1786039893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/SCS.0000000000009033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/scs.0000000000009033","relation":{},"ISSN":["1049-2275"],"issn-type":[{"value":"1049-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"2022-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}